CR10524A - Compuesto triciclico y uso farmaceutico del mismo - Google Patents

Compuesto triciclico y uso farmaceutico del mismo

Info

Publication number
CR10524A
CR10524A CR10524A CR10524A CR10524A CR 10524 A CR10524 A CR 10524A CR 10524 A CR10524 A CR 10524A CR 10524 A CR10524 A CR 10524A CR 10524 A CR10524 A CR 10524A
Authority
CR
Costa Rica
Prior art keywords
same
pharmaceutical use
tricycle compound
tricycle
compound
Prior art date
Application number
CR10524A
Other languages
English (en)
Inventor
Uchikawa Osamu
Koike Tatsuki
Hoashi Yasutaka
Takai Takafumi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR10524A publication Critical patent/CR10524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion proporciona un compuesto representado por la formula que resulta de utilidad como un agente para la profilaxis o tratamiento de enfermedades relacionadas con la accion de la melatonina, o una sal del mismo y similares.
CR10524A 2006-06-19 2008-12-18 Compuesto triciclico y uso farmaceutico del mismo CR10524A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006168518 2006-06-19

Publications (1)

Publication Number Publication Date
CR10524A true CR10524A (es) 2009-01-27

Family

ID=38519675

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10524A CR10524A (es) 2006-06-19 2008-12-18 Compuesto triciclico y uso farmaceutico del mismo

Country Status (35)

Country Link
US (5) US8030337B2 (es)
EP (1) EP2029561B1 (es)
JP (1) JP5222737B2 (es)
KR (1) KR101442274B1 (es)
CN (1) CN101506181B (es)
AR (1) AR061478A1 (es)
AU (1) AU2007261953B2 (es)
BR (1) BRPI0713743C1 (es)
CA (1) CA2655753C (es)
CL (1) CL2007001779A1 (es)
CO (1) CO6150175A2 (es)
CR (1) CR10524A (es)
CY (1) CY1115729T1 (es)
DK (1) DK2029561T3 (es)
ES (1) ES2523410T3 (es)
GE (1) GEP20125392B (es)
HR (1) HRP20141046T1 (es)
IL (1) IL195639A0 (es)
JO (1) JO2999B1 (es)
MA (1) MA30523B1 (es)
ME (2) ME01998B (es)
MX (1) MX2008015842A (es)
MY (1) MY158069A (es)
NO (1) NO341739B1 (es)
NZ (1) NZ574037A (es)
PE (1) PE20080941A1 (es)
PL (1) PL2029561T3 (es)
PT (1) PT2029561E (es)
RS (1) RS53616B1 (es)
RU (1) RU2456278C2 (es)
SI (1) SI2029561T1 (es)
TW (1) TWI402261B (es)
UA (1) UA99104C2 (es)
WO (1) WO2007148808A1 (es)
ZA (1) ZA200900151B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI402261B (zh) * 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
JP5291470B2 (ja) * 2006-12-28 2013-09-18 武田薬品工業株式会社 三環性化合物およびその医薬用途
CN103450111B (zh) * 2013-09-04 2015-07-08 温州大学 一种苯并噻唑杂环化合物的绿色合成方法
US20160253891A1 (en) * 2015-02-27 2016-09-01 Elwha Llc Device that determines that a subject may contact a sensed object and that warns of the potential contact
JP6893476B2 (ja) * 2016-01-08 2021-06-23 武田薬品工業株式会社 自閉症スペクトラム障害の予防または治療剤
AU2017205519B2 (en) * 2016-01-08 2022-01-27 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for delirium
CN110072882A (zh) 2016-10-19 2019-07-30 孟山都技术公司 用于改变开花和植物株型以提高产量潜力的组合物和方法
US20250228798A1 (en) * 2024-01-17 2025-07-17 Rivo Bio, Inc. Indane-, indene-, azaindane-, and azaindene-amines as activators of serotonin receptors
WO2025254130A1 (ja) * 2024-06-03 2025-12-11 株式会社ジェクスヴァル 遺伝子発現制御剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5654325A (en) 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
FR2725985B1 (fr) 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19502895A1 (de) 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
US5753709A (en) 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
CA2176854A1 (en) 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
FR2742153B1 (fr) 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP0885210B2 (en) * 1996-03-08 2008-06-18 Takeda Pharmaceutical Company Limited Tricylic compounds having binding affinity for melatonin receptors, their production and use
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
WO2001013950A1 (en) * 1999-08-20 2001-03-01 Takeda Chemical Industries, Ltd. Percutaneous absorption agents
CA2650698C (en) * 2000-11-17 2013-05-28 Takeda Pharmaceutical Company Limited Copolyvidone-containing preparation
JP3633895B2 (ja) * 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
TWI402261B (zh) * 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物

Also Published As

Publication number Publication date
SI2029561T1 (sl) 2014-11-28
CN101506181A (zh) 2009-08-12
HRP20141046T1 (hr) 2014-12-19
BRPI0713743A2 (pt) 2012-11-06
US8552037B2 (en) 2013-10-08
CN101506181B (zh) 2011-12-07
CA2655753A1 (en) 2007-12-27
JP2009541202A (ja) 2009-11-26
MA30523B1 (fr) 2009-06-01
ZA200900151B (en) 2010-03-31
IL195639A0 (en) 2009-09-01
NZ574037A (en) 2011-10-28
CA2655753C (en) 2015-08-04
ME00582A (en) 2011-12-20
JO2999B1 (ar) 2016-09-05
KR101442274B1 (ko) 2014-09-22
RS53616B1 (sr) 2015-04-30
AU2007261953A1 (en) 2007-12-27
MX2008015842A (es) 2009-01-09
HK1130049A1 (en) 2009-12-18
BRPI0713743B1 (pt) 2020-03-17
CY1115729T1 (el) 2017-01-25
US20140011849A1 (en) 2014-01-09
US8895591B2 (en) 2014-11-25
TWI402261B (zh) 2013-07-21
AU2007261953B2 (en) 2012-11-08
UA99104C2 (uk) 2012-07-25
MY158069A (en) 2016-08-30
US20130079374A1 (en) 2013-03-28
PL2029561T3 (pl) 2015-03-31
US8030337B2 (en) 2011-10-04
GEP20125392B (en) 2012-02-10
CL2007001779A1 (es) 2008-01-04
US8349879B2 (en) 2013-01-08
ES2523410T3 (es) 2014-11-25
US20110190361A1 (en) 2011-08-04
NO341739B1 (no) 2018-01-15
RU2456278C2 (ru) 2012-07-20
PE20080941A1 (es) 2008-09-04
RU2009101299A (ru) 2010-07-27
EP2029561B1 (en) 2014-08-13
TW200815376A (en) 2008-04-01
WO2007148808A1 (en) 2007-12-27
BRPI0713743B8 (pt) 2020-05-19
JP5222737B2 (ja) 2013-06-26
PT2029561E (pt) 2014-11-12
DK2029561T3 (da) 2014-11-10
AR061478A1 (es) 2008-08-27
EP2029561A1 (en) 2009-03-04
KR20090023701A (ko) 2009-03-05
ME01998B (me) 2015-05-20
US20110196003A1 (en) 2011-08-11
US20090182023A1 (en) 2009-07-16
US8236837B2 (en) 2012-08-07
NO20090234L (no) 2009-02-12
CO6150175A2 (es) 2010-04-20
BRPI0713743C1 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
UY32730A (es) Inhibidores de cyp17
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
CL2016002970A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo.
UY32045A (es) Compuesto amida
BR112015020650A2 (pt) inibidores de histona demetilases
GT201400111A (es) Triazolopiridinas sustituidas
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR101740A1 (es) Terapia de combinación y composiciones
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
PA8850801A1 (es) Compuestos útiles para inhibir chk1